Liquidia Corporation (NASDAQ:LQDA – Get Free Report) insider Sarah Krepp sold 24,880 shares of the firm’s stock in a transaction that occurred on Thursday, June 11th. The stock was sold at an average price of $70.28, for a total value of $1,748,566.40. Following the completion of the sale, the insider directly owned 121,863 shares in the company, valued at approximately $8,564,531.64. This trade represents a 16.95% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Sarah Krepp also recently made the following trade(s):
- On Monday, June 1st, Sarah Krepp sold 276 shares of Liquidia stock. The stock was sold at an average price of $60.87, for a total value of $16,800.12.
- On Monday, April 13th, Sarah Krepp sold 4,557 shares of Liquidia stock. The stock was sold at an average price of $38.37, for a total value of $174,852.09.
Liquidia Stock Performance
Shares of NASDAQ LQDA traded up $0.57 during mid-day trading on Monday, hitting $71.80. The company had a trading volume of 2,103,774 shares, compared to its average volume of 1,741,705. The stock has a market cap of $6.39 billion, a price-to-earnings ratio of 512.89 and a beta of 0.57. Liquidia Corporation has a 12 month low of $11.85 and a 12 month high of $72.71. The company has a debt-to-equity ratio of 1.18, a current ratio of 2.22 and a quick ratio of 2.03. The firm’s 50 day simple moving average is $49.85 and its two-hundred day simple moving average is $40.96.
Wall Street Analyst Weigh In
LQDA has been the topic of several analyst reports. Zacks Research upgraded Liquidia from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, May 5th. Jefferies Financial Group restated a “buy” rating and issued a $60.00 target price on shares of Liquidia in a research report on Monday, May 11th. BTIG Research raised their target price on Liquidia from $50.00 to $59.00 and gave the company a “buy” rating in a research report on Monday, May 11th. HC Wainwright raised their target price on Liquidia from $67.00 to $75.00 and gave the company a “buy” rating in a research report on Friday, June 5th. Finally, Oppenheimer set a $75.00 price target on Liquidia in a research report on Friday, June 5th. Three analysts have rated the stock with a Strong Buy rating, five have given a Buy rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $60.29.
Check Out Our Latest Stock Analysis on LQDA
Hedge Funds Weigh In On Liquidia
Several hedge funds have recently modified their holdings of the company. Farallon Capital Management LLC increased its position in shares of Liquidia by 1.1% during the 4th quarter. Farallon Capital Management LLC now owns 8,656,038 shares of the company’s stock valued at $298,547,000 after purchasing an additional 90,400 shares during the period. Vanguard Group Inc. grew its holdings in shares of Liquidia by 1.3% in the 4th quarter. Vanguard Group Inc. now owns 4,013,888 shares of the company’s stock worth $138,439,000 after acquiring an additional 52,671 shares during the last quarter. Opaleye Management Inc. grew its holdings in shares of Liquidia by 9.5% in the 2nd quarter. Opaleye Management Inc. now owns 2,475,000 shares of the company’s stock worth $30,838,000 after acquiring an additional 215,000 shares during the last quarter. Bank of America Corp DE grew its holdings in shares of Liquidia by 18.7% in the 1st quarter. Bank of America Corp DE now owns 2,287,792 shares of the company’s stock worth $86,341,000 after acquiring an additional 360,372 shares during the last quarter. Finally, Caprock Group LLC grew its holdings in shares of Liquidia by 9.3% in the 4th quarter. Caprock Group LLC now owns 1,783,921 shares of the company’s stock worth $61,527,000 after acquiring an additional 151,832 shares during the last quarter. 64.54% of the stock is currently owned by institutional investors and hedge funds.
Liquidia Company Profile
Liquidia Technologies, Inc is a clinical-stage biopharmaceutical company headquartered in Research Triangle Park, North Carolina. The company leverages its proprietary PRINT® (Particle Replication In Non-wetting Templates) platform to engineer precisely shaped and sized drug particles, with the goal of improving delivery, efficacy and safety profiles. By controlling particle characteristics at the nanoscale, Liquidia seeks to enhance respiratory and other therapies that depend on targeted delivery.
The company’s lead product candidate, LIQ861, is a dry powder formulation of treprostinil designed for inhalation in patients with pulmonary arterial hypertension (PAH).
Read More
- Five stocks we like better than Liquidia
- These 5 Companies Just Made a Massive Bet on Themselves
- 5 Stocks Built to Thrive in a Higher-for-Longer Economy
- RH’s Strong Q1 Still Leaves Investors With One Big Question
- Iran Ceasefire or Not, These 3 Companies Could Win
Receive News & Ratings for Liquidia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Liquidia and related companies with MarketBeat.com's FREE daily email newsletter.
